Inhibition of NADPH oxidases prevents the development of osteoarthritis
Echinochrome a release by red spherule cells is an iron-withholding strategy of sea urchin innate immunity
The copper-mediated inhibition remains localized, potentially reducing follicle sensitivity to DHT without affecting hormones elsewhere in the body
The findings suggest the drug that sheds the most weight is not the one with the strongest evidence of protecting the heart, and can also trigger the most lean mass loss and the most side effects

So here are some takeaways on the longevity of the obesity platform: Even without GLP-1 craze they grew the business (profitably?) to a $100M run-rate in 7 months with oral weight loss medications alone We will see a flood of new GLP-1 medications enter the market and the situation will move quickly and be fluid including the introduction of oral compounds that may lead to other use-cases for Hims There is some sort of precedent that compounding certain elements like end-dosage or side effect mitigation is considered clinically necessary and therefore defensible Hims & Hers will also offer brand-name GLP-1s on platform, maybe alluding to expectations of reduction in out of pocket cost over time, or an increase in supply My unsolicited thoughts for Hims would be to take advantage of this huge surge in cash and invest it into the sustainable, growing parts of the business
MDD is also marked by systemic inflammation with high cytokines IL-6, TNF-, and IL-1 (Troubat et al., 2021)